Special Issue

Drug Candidates for the Treatment of Glioblastoma

Message from the Guest Editor

Glioblastoma multiforme (GBM) is a lethal central nervous system malignancy with a median patient survival of a few months. Currently, due to complex signaling pathway activation, there is no cure for GBM, and the first-line drug temozolomide (TMZ) can only prolong the life expectancy of treated patients. Cancer vaccine and new drug is an attractive option as it aims to induce a durable response or therapeutic relevance to eradicate GBM.

We welcome articles on the development of new pharmacologically active compounds and the continued use of natural products, synthetic and existing drugs as new drug developments for the treatment of GBM. We welcome your review and original articles that shed light on the challenges and opportunities in the development of GBM treatment drugs. Topics include: new positioning of GBM treatment drugs, selective optimization and reduction of side effects, and the origin and application of synthetic drugs or drug metabolites as new drugs, drug delivery system, nanomaterial applications. The collection of manuscripts will be published as a special issue of the journal.

Guest Editor

Prof. Dr. Yi-Chiang Hsu

School of Medicine, I-Shou University, Kaohsiung 82445, Taiwan

Deadline for manuscript submissions

closed (5 March 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/171954

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

